Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
2025 · 4th Quarter (Oct 1 - Dec 31)
VIR BIOTECHNOLOGY, INC.
Filed by FORBES-TATE.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 18, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- FORBES-TATE
- Client
- VIR BIOTECHNOLOGY, INC.
- Filing UUID
- 1b536114-de18-4173-850f-9da1ac960d0c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.